Therefore, optimizing the systemic distribution and circulation time of IL-22 through structural or formulation modifications is of importance to enhance its efficacy against MASLD and reduce side effects (Zai et al., 2019). The gene discussed is IL22; the disease is metabolic dysfunction-associated steatotic liver disease.